Berberine and Cholestatic Liver Disease: Clinical and Molecular Hepatology | March 2026

Introduction

Cholestatic liver disease (CLD) is a progressive condition characterised by impaired bile formation and flow, leading to bile accumulation, liver injury, and eventual cirrhosis or liver failure. Despite advances in hepatology, treatment options remain limited, with ursodeoxycholic acid and obeticholic acid offering only partial benefit. Increasing attention has been directed toward the gut–liver axis, particularly the role of gut microbiota and their metabolites in modulating liver disease.

Problem Statement

The key mechanisms driving CLD progression remain incompletely understood, and current therapies fail to adequately halt disease progression in many patients. Although berberine has shown hepatoprotective effects, its very low systemic bioavailability raises uncertainty about how it exerts clinical benefit, suggesting an indirect mechanism possibly mediated through gut microbiota.

Summary

This study demonstrates that orally administered berberine is converted by gut microbiota into dihydroberberine, which acts as the active metabolite. Dihydroberberine suppresses serotonin (5-HT) production in intestinal enterochromaffin cells by inhibiting tryptophan hydroxylase 1, thereby disrupting the 5-HT signalling axis involved in cholestatic injury. This mechanism was consistently validated across multiple animal models and further supported by clinical data showing improved biochemical markers and reduced 5-HT levels in patients. These findings highlight a novel microbiota-driven therapeutic pathway, positioning berberine as a promising candidate in CLD management.